医学
髓系白血病
急性早幼粒细胞白血病
重症监护医学
威尼斯人
肿瘤科
临床试验
白血病
内科学
生物化学
基因
化学
慢性淋巴细胞白血病
维甲酸
作者
Daniel Aaron Pollyea,Jessica Kaplan Altman,Rita Elias Assi,Kimo Bachiashvili,Vijaya Raj Bhatt,Amir Tahmasb Fathi,Kateryna Fedorov,James M. Foran,Ivana Gojo,Aaron Goldberg,Aric C. Hall,Brian A. Jonas,Matthew R. Levine,James Mangan,Gabriel N. Mannis,Guido Marcucci,Alice S. Mims,Kelsey Moriarty,Moaath Mustafa Ali,Jadee Neff
标识
DOI:10.6004/jnccn.2026.0028
摘要
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI